Glooko adds former Eli Lilly exec to its board of directors

Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors.

Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Terumo, Glooko partner for diabetes data sharing with insulin patch pump

Left: Terumo’s Medisafe With insulin patch pump. Right: insulin patch pump data upload via Glooko’s mobile app. [Images from Terumo and Glooko]Terumo (TSE:4543) and Glooko today announced a collaboration to integrate their technologies and create new diabetes data sharing solutions.

In the new technology integration, users with diabetes will be able to transfer recorded data from the Terumo Medisafe With insulin patch pump into the Glooko management platform, allowing for the visualization of insulin dosage, food and activities in graphs.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Glooko acquires Diabnext and its digital health platform for managing diabetes

The Glooko XT platform. [Image from Glooko]Glooko announced today that it acquired Diabnext, a developer of a digital health platform for managing diabetes and connecting to healthcare providers.

Paris-based Diabnext’s mobile app tracks diabetes data so that physicians can collaborate with their patients to monitor individual patient data and provide remote care. Financial details of the acquisition were not disclosed.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Lilly partners with four companies on insulin pen tech

Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with on Lilly’s latest insulin pen.

The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will pair with software and/or medical devices offered by Dexcom (NSDQ:DXCM), Glooko, myDiabby Healthcare (Bordeaux, France) and Roche, with its mySugr app, to facilitate the integration of personalized data and actionable insights.

Get the full story on our sister site, Drug Delivery Business News.

Read more
  • 0

Glooko raises $30M Series D

Diabetes and obesity management tech developer Glooko announced today that it raised $30 million in a Series D financing round.

Palo Alto, Calif.-based Glooko, which develops remote patient monitoring and chronic care management products including data management technologies for insulin delivery devices, said in a news release that proceeds from the financing will be used to accelerate organic growth and strategic initiatives across its product line.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0